ArticleEuropean oral research2025
Comparison of calcium silicate-based materials in pulpotomies of primary molars: a randomized clinical trial.
Article in European oral research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The primary objective of this investigation is to evaluate the clinical and radiographic findings of mineral trioxide aggregate (MTA) and Biodentine (BD) as pulpotomy agents in primary molars. Materials and methods: Two hundred primary molars (N=200) were treated with pulpotomy. Clinical and radiographic outcomes, including both successes and failures, were documented throughout a 36-month follow-up period. Statistical analyses were performed using the Fisher Exact, McNemar, and Chi-Square tests. Results: No statistically significant differences in success rates were found between the 1-, 3-, 6-, 24-, and 36-month assessments for each material when evaluated independently. However, at the twelfth month, the clinical and radiographic success rates for MTA (98% and 92%, respectively) were significantly higher than those for BD (90% and 80%, respectively) with a p-value of less than 0.05. Conclusion: In this study, MTA demonstrated greater success than BD at 36 months. Nevertheless, higher quality randomized controlled trials with longer follow-up periods are necessary to obtain more reliable results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.